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Abstract
Psoriasis is a skin disease mainly developed in humans, although it is also seen in mon‐
keys and dogs. Animal models with psoriasis‐like lesions have been a key factor for its 
understanding. Xenotransplants of human psoriatic skin in immunodeficient mice were 
the first approach for the association of immunologic problems with the development 
of psoriasis and have been also useful for the evaluation on new therapeutic agents. 
Imiquimod‐induced murine psoriasis is nowadays one of the most used animal models 
to study this disease, perhaps because healthy wild‐type mice are used, which means that 
it is an affordable model, easy to generate, and, more importantly, resembles the inflam‐
matory, angiogenic and hyperproliferative characteristics of human psoriasis. Several 
transgenic (over‐expressing VEGF, Tie2, TGFβ, STAT3, IL‐36, PPARβ/γ) and knockout 
(lacking IκBα, JunB, IFNR‐2, IL‐36RA, CD18, IKK2) mice have been useful for the associa‐
tion of specific molecules for the development of psoriasis. Other approach has been the 
use of both transgenic/knockout mice and imiquimod treatment, where the importance 
of βTrCP, IκBζ, IL‐35 and Tnip1 for the development of psoriasis was found. In this chap‐
ter, some of these animal models are discussed.
Keywords: psoriasis, animal models, skin immunology, angiogenesis, keratinocytes
1. Introduction
Psoriasis is a disease that has been accompanying the existence of humans. The ancient Greeks 
described an illness that seems to be psoriasis, but it could be confused with leprosy or Hansen’s 
disease [1]. Because psoriasis develops naturally in humans but rarely in other species [2, 3], the 
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study of this disease was possible only after progress was made on immunology and on genetic 
engineering knowledge. Although reports on animals with psoriatic lesions due spontaneous 
mutations exist, the phenotype does not completely resemble human psoriasis, as occur with the 
homozygous asebia (Scd1ab/Scd1ab) mutant mice, the Flaky skin mice (Ttcfsn/Ttcfsn) and the 
spontaneous chronic proliferative dermatitis mutation mice [4, 5]. Now, with the advances on 
genetic engineering, some transgenic animals and animals with targeted mutations (knockout 
and knock‐in) have been developed to study psoriasis. In the case of knockout models, the tar‐
geted gene is inactivated and the phenotype is caused by the absence of the targeted gene prod‐
uct. In the case of knock‐in model, the gene is modified through targeted point mutation, with the 
addition or deletion of a nucleotide, instead of complete disruption of the target gene expression, 
and the phenotype depends on the expression of modified gene products. Knockout and knock‐
in animals are also developed with the use of tissue specific promoters to eliminate or express the 
targeted gene, and even more, the expression or suppression of the gene could be controlled by 
specific promoter regulators, where antibiotics and hormones are frequently used [6].
Another strategy to study psoriasis and other dermatologic illnesses in vitro is the develop‐
ment of 2nd‐ or 3rd‐dimensional cell co‐cultures. These systems have the limitation that so far 
has not been possible to include all the cellular types that are part of the skin, but have been 
very useful to evaluate new drugs for treatment [7].
2. Immunological factors in psoriasis
2.1. Humanized animal models (xenotransplantation)
Xenotransplantation was the first approach generated as animal model for the study of pso‐
riasis and for the evaluation of anti‐psoriatic treatments that consists in the transplantation of 
human skin in the back of inmunodeficient mice. In 1994, the first murine psoriasis model done 
in mice with severe combined immunodeficiency (SCID) was described. These mice have the 
so‐called scid mutation that affects the “protein kinase DNA activated catalytic polypeptide” 
(Prkdc/DNA‐PKcs), causing a defect in the antigen receptor gene rearrangement of lymphocytes, 
and consequently a SCID of the T‐ and B‐cell systems [8]. In these mice, the psoriatic phenotype 
is kept for 2 months, enough time for the analysis of the disease. Later, it was demonstrated that 
mice with non‐psoriatic human skin transplants that received lymphocytes from the psoriatic 
skin developed psoriasis; these facts demonstrated the importance of the immunologic factor 
for the development of this disease [9]. Also, the so‐called nude mice are used to study psoriasis; 
these mice have a mutation in the forkhead box transcription factor N1 that results in defective 
thymus development, and therefore in lack functional T cells, or nude mice that lack recombinase 
activating genes 1 (Rag1) and 2 (Rag2) involved in the development of T and B cells.
2.2. Imiquimod‐induced murine psoriasis (IMQ‐Mu‐Pso)
This transient model of psoriasis‐like disease was developed by Van der Fits et al. [10], using non‐
genetically modified healthy mice daily treated with topic imiquimod or resiquimod (TLR7‐TLR8 
ligand) for 6 days. This simple model shows wide characteristics described in the human psoriatic 
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skin lesions, including: activation of pDC, Th17 cells producing IL‐17, IL‐22 and IL‐23, activation 
of angiogenic process and hyperproliferacion of keratinocytes. IMQ‐Mu‐Pso model is generated 
due to an acute inflammation in the epidermis induced by imiquimod, hyperactivating the innate 
immunity and leading the adaptive immunity to produce great amounts of IL‐17. IL‐17, in turn, 
induces angiogenesis and proliferation of keratinocytes, as biological characteristics of psoriatic 
lesions. IMQ‐Mu‐Pso also demonstrated that undisrupted molecular and cellular mechanisms 
are able to break inflammation, as mice used for this model are healthy mice that show the high‐
est production of inflammatory cytokines on the third day of treatment and show the highest 
development of psoriatic skin on the sixth day, but after this time, the mice are able to revert the 
inflammatory process as they are not genetically compromised. The short lasting presence of pso‐
riatic lesions is an inconvenience of this model, although it has been widely used to elucidate the 
pathogenesis of psoriasis, and very interesting data have been published [10].
2.3. Intestinal microbiome affects the induction of psoriasis
The absence of 100% concordance between monozygotic twins suggests a crucial role of environ‐
mental factors for the development of psoriasis, as only 35–75% of monozygotic twins develop 
psoriasis; alcohol intake and smoking are considered non genetic factors that predispose indi‐
viduals to develop psoriasis [11]. Intestinal microbiota has an important effect on the develop‐
ment and function of the immune system, for instance, a specific subset of microbiota has been 
shown to play roles in the development of Th17, meanwhile other subset favors the develop‐
ment of Treg cells [12]. Another study showed that microbiota from skin of psoriatic patients is 
different from healthy subjects; Proteobacteria were present at significantly higher levels in the 
psoriatic skin compared to limb skin used as control (52 vs. 32%, p = 0.0113), and in the same 
study, both Staphylococci and Propionibacteria were significantly lower in psoriasis versus control 
(p = 0.051, 0.046, respectively) [13]. In 2015, Zanvit et al. demonstrated that psoriasis is medi‐
ated by the early interaction between certain subset of bacterial microbiota and cells of immune 
system [14]. They treated 4‐week‐old mice with oral antibiotics (vancomycin and polymyxin B) 
showing a decrease in the severity of psoriasis compared to mice without antibiotics using the 
IMQ‐Mu‐Pso model. IL‐17+ and IL‐22+ T cells were significantly decreased in skin and gut in the 
antibiotic‐treated mice; however, the Foxp3+ Treg cells were significantly increased in the skin 
of these mice. In contrast, when neonatal mice received the antibiotic treatment and the psoriasis 
was induced with imiquimod as 4‐week old, they observed an increase in the severity of disease 
compared to mice without antibiotic treatment evidenced by the presence of immunological 
cells infiltration and by the increase of thickness in dermis; besides they did not find augment of 
IL‐17+ cells, but significant increase of IL‐22+ cells. The intestinal microbiota was also consider‐
ably different between mice treated with antibiotics as adults from those treated as neonates [14]. 
These results settle that among the factors that predispose to psoriasis is intestinal microbiota 
that depends on breast feed as neonates, type of food intake, but also on the use of antibiotics.
2.4. Disruption of NFκB and AP‐1 to generate psoriasis in animal models
Innate immunity in skin is mediated by the activation of membrane receptors expressed on 
dendritic cells, Langerhans cells and macrophages activated by pathogens‐ or damage‐molec‐
ular patterns (PAMP or DAMP). After ligand‐receptor interaction, molecular signaling events 
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occur into the cell leading to the activation of transcription factors, such as NFκB and AP‐1 that 
translocate into the nucleus for the expression of cytokines and antimicrobial peptides [15]. The 
malfunctioning in the regulation of the activity of these transcription factors could lead to the 
development of psoriatic lesions, as we next describe.
In unstimulated cells, NFκB dimers are sequestered in the cytoplasm by a family of inhibitors 
called IκB (Inhibitor of κB), and the IκB proteins mask the nuclear localization signals (NLS) 
of NFκB proteins and keep them sequestered in an inactive state in the cytoplasm. Activation 
of NFκB is initiated by the signal‐induced degradation of IκB proteins; this occurs primarily 
by the activation of a kinase called IκB kinase (IKK). When activated by PAMPs or DAMPs, 
IKK phosphorylates two serine residues located in IκBα’s regulatory domain, and then IκBα 
is ubiquitinated and degraded by the proteasome. With the degradation of IκBα, NFκB dimer 
is freed to enter into the nucleus to initiate the expression of specific genes that have DNA‐
binding sites for NFκB at their promoter site. The transcription of the targeted genes initiates 
a physiological response, for example, inflammation, cell survival and cellular proliferation. 
In fact, NFκB turns on the expression of its own repressor, IκBα. The newly synthesized IκBα 
then inhibits NFκB activity controlling the function of NFκB in an oscillatory way [15].
In IMQ‐Mu‐Pso, the severity of psoriatic lesions has been associated with a reduced pres‐
ence of IκBα due over‐degradation and in consequence with an enhanced NFκB activation. 
IκBα knockout mice developed psoriasis and died within the 7th–10th day after birth. The 
histological analysis showed myelopoietic tissues enlarged and diffusely distributed, and also 
alterations in the liver with enhanced splenic extramedullary hematopoiesiswith increased 
presence of monocytes/macrophages was seen [16].
“β‐transducin repeat‐containing protein” (β‐TrCP) serves as substrate recognition component 
of E3 ubiquitin ligase that control the stability of important regulators of signal transduction, 
including IκBα. Mice with down‐regulation of βTrCP ameliorate IMQ‐Mu‐Pso skin lesions, 
as IκBα does not degrade, keeping NFκB into the cytoplasm. This interesting finding suggests 
that βTrCP could be a novel target for developing agents to treat psoriasis, since it is involved 
in the NFκB signaling to regulate inflammation [17].
IκBζ is another molecule that interacts with NFκB, but inside the nucleus. This molecule 
has been recently identified as a key regulator in the development of psoriasis [18]. IκBζ is 
increased in psoriatic skin compared to non‐psoriatic skin from the same patient. Some stud‐
ies suggest that IκBζ associates with NFκB p50 subunit and binds to specific IκBζ response 
elements located in the promoter region of targeted genes consisting of NFκB‐ and C/EBP 
(CCAAT/enhancer‐binding protein)‐binding sites and exerts its transcription‐enhancing activ‐
ity on secondary response genes primarily by chromatin remodeling [19]. IκBζ is expressed 
in human keratinocytes induced with IL‐17 and is a direct transcriptional activator of TNFα/
IL‐17‐inducible psoriasis‐associated proteins such as IL‐8, IL‐17C, IL‐17A22, IL‐19, IL23, IL22, 
CCL20 and hBD220. Interestingly, in imiquimod‐treated IκBζ‐deficient mice, psoriatic skin is 
not observed, and the molecules induced by TNFα/IL‐17 are significantly down‐expressed [20].
The dysfunctional activity of other transcription factors, for instance, AP‐1 and STAT3, also 
contributes to skin inflammation development [21]. Mice with deficient expression of JunB 
and c‐Jun, and mice with over‐expression of FOS, generate a phenotype resembling the 
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histological characteristics of psoriasis, including the production pro‐inflammatory cyto‐
kines. Besides, JunBexpression is reduced in epidermal keratinocytes of psoriatic patients 
in comparison with cells from healthy subjects [21]. Moreover, STAT3 transgenic mice and 
SOCS3 knockout mice (the negative regulator of STAT3) have constitutive activation of 
STAT3 and both develop murine IL‐6‐driven psoriasis [22, 23].
2.5. The role of cytokines in psoriasis
Other sort of psoriatic animal models includes those where cytokines and cells of immune 
system are involved. The importance of type I interferons in the psoriasis was demonstrated 
in “IFN regulatory factor‐2” (IFNR‐2)‐deficient mice, a transcriptional repressor for IFN‐αβ 
signaling. These mice developed skin lesions similar to human psoriasis [24], in fact, type I 
interferons promote the activation of dermal dendritic cells (dDCs) [25].
Another cytokine with importance for the development of psoriasis is IL‐36, an IL‐1 family 
sub‐member. The over‐expression of IL‐36α in transgenic murine (K14/IL‐36) keratinocytes 
promotes acanthosis, hyperkeratosis, cells infiltration and increased expression of cytokines 
and chemokines [26]. The deficiency of IL‐36RA (the natural antagonist of IL‐36) in IL‐36α 
(K14/IL‐36, IL‐36RA−/−)‐transgenic mice exacerbates the severity of psoriasis; histological 
analysis reveals intracorneal and intraepithelial pustules, parakeratotic and orthokeratotic 
hyperkeratosis, dilated superficial dermal blood vessels, and dermal inflammatory infiltrate. 
Additionally, mice deficient to IL‐36 or in its receptor IL‐36R are protected from IMQ‐Mu‐Pso 
[26]. In turn, IL‐1β, TNFα, and IL‐36 activate dDC and induce the production of IL‐23, nec‐
essary for naive T cells to polarize to Th17, suggesting that IL‐23 could be the link between 
the innate and adaptive immune response that occur in psoriasis [27]. In fact, it is possible to 
obtain psoriasiform skin in wild‐type mice with nothing more but the inoculation of recombi‐
nant IL‐23 or IL‐17 [28]. In contrast, IL‐35 has a potent immunosuppressive effect on HaCaT 
keratinocytes treated with TNF‐α and IL‐17 suppressing the expression of IL‐6, CXCL8, and 
S100A7 [28]. In IMQ‐Mu‐Pso and K14‐VEGF transgenic mice model, IL‐35 reduced M1 mac‐
rophages (F4/80+CD80+), whereas anti‐inflammatory M2 macrophages (F4/80+CD206+) were 
increased in the spleen and ear. IL‐10–secreting CD4+, FoxP3+, CD25+ T cells were increased 
in those tissues, although IL‐10–secreting CD25‐T cells were also increased [29]. These results 
suggest that IL‐35 treatment for psoriasis increases M2 macrophages as well as IL‐10 produc‐
tion but suppresses Th17 cells development, consistent with the effect of IL‐35 on Treg expan‐
sion, although not all IL‐10 was secreted by Treg cells.
2.6. Cellular immunology in psoriasis
The insufficient regulation of specific cellular immune response is also involved in the devel‐
opment of psoriasis [30]. In normal conditions, Treg cells regulate the activity of auto‐reactive 
Th1 and Th17 cells, but in psoriasis Treg cells might not be functional, as was evidenced in 
the CD18hypo mouse model [31]. Homozygous PL/J CD18 hypomorphic (CD18hypo)‐mice 
developed spontaneously psoriasis‐like skin in 12‐ to 14‐week‐old mice. CD18 is a molecule 
that together with CD11a constitutes an adhesion molecule of the β2 integrin family, impor‐
tant for the complete function of Treg cells. It has been suggested that CD18hypo mice induce 
psoriasis because CD18‐low expressing Treg cells, or with a not fully active molecule, cannot 
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regulate the activity of auto‐reactive Th1 and Th17 cells, since these mice improve when Treg 
cells from normal mice are transferred [32]. In CD18hypo mice, psoriatic lesions meliorate 
when macrophages are eliminated by the use of clodronate liposomes in the skin [33]. These 
results show the importance of Treg cell and macrophages in the evolution of psoriasis.
2.7. Implantable synthetic cytokine‐converter cells model
Schukur et al. [34] designed the so‐called implantable synthetic cytokine converter cells system 
based on the observation that psoriatic patients have high concentrations of TNFα and IL‐22, 
and on the fact that IL‐4 and IL‐10 cytokines have an important anti‐psoriatic effect. Considering 
the previous, they generated by genetic engineering human cells to react to high concentra‐
tions of TNFα and IL‐22; these cells would be implanted to psoriatic patients and activated by 
TNFα and IL‐22 from a psoriatic flare, and as a result, they would produce therapeutic doses 
of IL‐4 and IL‐10 to control inflammation. To achieve the goal, HEK‐293T cells were co‐trans‐
fected with the plasmids pNFκB‐hIL‐22RA‐pA, phCMV‐hSTAT3‐pA, pSTAT3‐mIL‐4‐pA and 
pSTAT3‐mIL‐10‐pA. The authors first confirmed that co‐transfected cells produced important 
levels of IL‐4 and IL‐10 when stimulated with TNFα and IL‐22 in vitro [34]. TNFα activated the 
production of IL‐22 receptor, and in turn IL‐22 activated STAT3 signaling to induce the pro‐
duction of IL‐4 and IL‐10, to generate an anti‐inflammatory environment. When co‐transfected 
HEK‐293T cells were intraperitoneally implanted into mice with IMQ‐Mu‐Pso the cytokines 
associated with the pathogenesis of psoriasis, such as IL‐17, IFNα and C‐X‐C motif chemokine 
9 (CXCL9), decreased substantially and a considerable increase in the production of the anti‐
inflammatory cytokines IL‐4 and IL‐10 was observed on day 5. Only the skin of animals with 
implanted co‐transfected cells containing the antipsoriatic cytokine converter showed reduced 
skin lesions, evidenced by the reduction of erythema, scaling, and thickening. This is an inter‐
esting approach to treat psoriasis, although the complexity relies on the requirement to co‐
transfect cells from every single patient to avoid transplant rejection. Meanwhile, this system 
was also evaluated in vitro using blood from psoriatic patients and from healthy individuals, 
and interestingly only in blood from psoriatic patients increased levels of anti‐inflammatory 
cytokines were detected [34].
3. Angiogenic factor in psoriasis
The altered function of angiogenic molecules also produces psoriasis. “Vascular endothelial 
growth factor” (VEGF)‐transgenic mice [35], “endothelial specific receptor tyrosine kinase” 
(K5‐Tie2)‐transgenic mice [36], and “transforming growth factor beta 1” (K5‐TGFβ1)‐trans‐
genic mice [37] are psoriasis animal models that highlight the importance of angiogenesis in 
this pathology. VEGF is a crucial factor that mediates the angiogenesis of blood vessels and 
is highly expressed in the psoriatic skin lesions. VEGF induces microvascular alterations in 
the dermal papillae, which facilitate the development and persistence of the psoriatic lesions 
[35]. Moreover, the increased vasculature and permeability provide nutrition to the hyperp‐
roliferating keratinocytes and promote the migration of inflammatory cells. The 6‐month‐ old 
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K14‐VEGF mice develop psoriasis, but if these mice are treated with imiquimod at 8‐week old, 
the skin thickens, chemokines CXCL‐9/10, CCL‐20 and CCR6 increase, cytokines IL‐23, IL‐17, 
TNFα, and (IFN)‐γ rise, and the cells CD11c+ DCs, Th17, Th1, γδ‐T increase. In wild‐type mice 
IMQ‐Mu‐Pso skin lesions last until day 7 of treatment, but in K14‐VEGF mice treated with 
imiquimod, all the parameters described above are stable until day 14 [38]. This combined 
model IMQ‐K14‐VEGF is more appropriate for long‐term studies compared to IMQ‐Mu‐Pso 
model, which is only an acute chemical‐stimulated model.
Tie2 is the angiopoietin receptor that together with VEGF is essential for proliferation, mat‐
uration and for the maintenance of blood vessels. Hyperproliferation of keratinocytes and 
abundance of immunological cells infiltration, including Th17 cells, are detected in psoriatic 
skin. The over‐expression of VEGF is promoted by TGFβ but also can be regulated by HIF‐1α, 
as it is over‐expressed in the psoriatic skin [36].
4. The role of keratinocytes in psoriasis
4.1. PPAR β/δ
The “peroxisome proliferator‐activated receptor” (PPAR β/δ) transgenic mice, and the human 
keratinocytes autocrine growth factor (amphiregulin) transgenic mice [39, 40] both resemble 
psoriasis because they participate in the proliferation and differentiation of keratinocytes [41]. 
PPAR β/δ receptor is induced by TNFα, contributes to STAT3 phosphorylation, blocks apop‐
tosis in keratinocytes, induces angiogenesis, and is up‐regulated in human psoriatic skin [42]. 
In fact, PPAR β/δ directly induces the differentiation of keratinocytes, and in the transgenic 
mouse model, a light augment of Th17 is observed [43].
4.2. NFκB inhibits proliferation in keratinocytes
Genome‐wide association studies suggest a link between psoriasis and the NFκB pathway, 
and this proposal has been supported by mouse models. Evidence gathered from diverse 
studies has shown that NFκB has a growth inhibitory function in the skin. Mice with epi‐
dermis‐specific deletion of IKK2 (which mediates canonical NFκB activation) develop severe 
inflammatory skin disease that is mediated by TNFα, suggesting the critical function of 
IKK2‐mediated NFκB activity in epidermal keratinocytes to regulate mechanisms that main‐
tain the immune homeostasis of the skin [44].
Grinberg‐Bleyer, et al. [45] described a murine psoriasis model that lacks the expression of 
p65 and c‐Rel in epidermal cells. After birth, these mice developed severe psoriasis; early 
lesions were well‐demarcated, scattered and rigid, with scaly plaques without edematous or 
exudative reaction aspect. H&E staining revealed epidermal thickening, hyperkeratosis and 
focal parakeratosis, as well as mononuclear infiltrates in the epidermis, which are features of 
psoriatic lesions. In this model, psoriatic lesions were resolved 30 days after birth by Treg cells 
effect, but when these cells were eliminated by the use of anti‐CD25 antibodies, the  deficient 
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mice showed a worsened pathology and the psoriatic lesions were reversed with anti‐TNFα 
treatment [45]. Also RelA has a growth‐inhibitory role in keratinocytes and prevents their 
differentiation [46]. Together, these results indicate that activation of canonical NFκB path‐
way in keratinocytes is required for their optimal differentiation and for the maintenance of 
immune homeostasis in the skin.
4.3. Prokineticin 2
Prokineticin2 (PK2), also named Bv8, is a small 8 KDa protein found in serum and dermis of pso‐
riatic patients. PK2 participates in numerous important physiological processes including inflam‐
mation, neurogenesis, tissue development, angiogenesis, and even nociception [47, 48]. This peptide 
is mainly expressed in brain but can also be found in skin, bone marrow, lymphoid organs, 
granulocytes, dendritic cells and macrophages [49]. He et al. [50] found that bacterial products, 
including LPS and DNA, promoted in macrophages the production of PK2 and inflamma‐
tory factors, suggesting that infection is a primary inducer of PK2. The authors demonstrated 
that in macrophages PK2 induced high production of IL‐1β, and in keratinocytes and fibroblast 
co‐cultures PK2 induced IL‐6, IL‐8 and GM‐SCF. In vivo PK2 promoted the differentiation of 
fibroblast and keratinocytes [51]. Besides, when PK2 was over‐expressed in psoriasis‐K14‐VEGF 
transgenic mouse model, psoriatic lesions were gradually aggravated, as evaluated by increase 
of redness, swelling, weight, thickness, scaly epidermis, keratinocyte hyper‐proliferation, and 
increase of IL‐1β, TNFα, IFNγ, IL‐12, IL‐22, IL‐23, IL‐17 in the ear; moreover, increase of lymph 
node weight was also seen. On the contrary, in psoriatic‐K14‐VEGF transgenic mouse model 
with PK2 down‐regulated, the psoriatic lesions were abrogated [50]. The results suggest that PK2 
aggravates psoriasis by the promotion of keratinocytes and fibroblasts proliferation, inflamma‐
tion, and angiogenesis.
4.4. Tnip1
The big dilemma about psoriasis is whether the root of the problem falls on keratinocytes 
or on immunological cells dysfunction. It has been well described that IL‐23‐producing 
myeloid cells and IL‐17–producing T cells are abundant in psoriatic skin, and that IL‐23 and 
IL‐17 induce in keratinocytes and fibroblasts high production of chemokines, which in turn, 
recruit even more immunological cells creating a feedback loop that worsens the disease. 
In keratinocytes and immunological cells, “TNFAIP3‐inter‐acting protein 1” (Tnip1) down‐
regulates the chemokines production induced by IL‐17 [50]. Ippagunta et al. [52], using the 
IMQ‐Mu‐Pso model under the Tnip‐keratinocyte‐specific‐deletion mice (Tnip1flox/flox K14‐
Cre), found that keratinocytes contribute intrinsically to psoriasis because when keratino‐
cytes lost Tnip1 function they could not control the production of chemokines induced by 
IL‐17. Tnip1flox/floxK14‐Cre mice developed severe psoriasis when low doses of imiquimod 
were used, even at concentrations on which WT mice do not develop psoriasis. Interestingly, 
when bone marrow cells from Tnip1‐/‐ mice were transferred to WT mice and treated with 
low doses of imiquimod, they did not developed psoriasis, confirming that the lack of func‐
tion of Tnip1 in keratinocytes and fibroblast, but not in hematopoietic lineage cells, generate 
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psoriasis [52]. With these results, the authors provide evidence that specifically skin‐resident 
keratinocytes contribute causally to psoriasis.
5. In vitro models for the study of psoriasis
As we previously mentioned, animal models have been very useful to dissect the molecular 
and cellular mechanisms for psoriasis development. These models have been also advanta‐
geous to evaluate new pharmaceuticals, nevertheless the physiology, anatomy and molecular 
differences between animal models and humans cause that only around 10% of new treat‐
ments assayed on phase I, be really useful in humans [53]. Although humanized models have 
also been developed, immunodeficient animals are most commonly used. Alternative meth‐
ods have been developed to analyze the effect of new anti‐psoriatic drugs; 2D, 2D+membrane, 
and 3D cell cultures have been designed [54]. 2D model consists of primary explants of kera‐
tinocytes or fibroblasts from psoriatic patients cultured over extracellular matrix proteins to 
evaluate cellular proliferation, cellular differentiation and cytokines production [55]. In the 
2D+membrane model, two cell types are co‐cultured separated by a synthetic membrane to 
evaluate the interconnection between two cell types in the pathology [56]. 3D cultures, also 
known as organotypic culture system (OCS), allow the growth of complex biological systems 
in vitro in a way that resembles part of their normal physiology and function. OCSs are pow‐
erful as experimental platforms in preclinical dermatological research, helping to validate 
mechanisms of diseases and to test the therapeutic potential of candidate drugs [57]. The new 
generation of 3D cultures connected to biosensors or chips allows real‐time monitoring of 
biological parameters such as loss of water and electrophysiologic parameters [58].
6. Conclusion
The actual hypothesis about the cellular and molecular mechanisms that lead to the develop‐
ment of psoriatic lesions has been established by the use of animal models. The use of xeno‐
transplants confirmed the important role of immunology in this disease. The studies done in 
genetically modified mice that overproduce (transgenic) or lack (knockout) certain proteins 
reveal specific protagonists of innate or adaptive immunity, angiogenesis or proliferation for 
the development of psoriasis.
In Figure 1, we represent a developing inflammation mechanism generated in the skin of 
healthy individuals denoted as a brown cogwheel system, where a trigger induces the innate 
and adaptive immune response, and in turn angiogenesis and keratinocytes proliferation 
are activated. Every cog represents one participant in inflammation: cell (DCs, macrophages, 
iLC IL‐17+, Th1, Th17, keratinocytes, between others) or molecule (TLRs, NFκB, βTrCP, IκBζ, 
Stat3, TNFα, IFNα, IL‐12, IL‐36, IL‐23, Th1, IL‐6, Th17, IL‐17, CCR6, VEGF, Tie2 TGFβ1, 
PPARαβ, PK2, between others). The red arrows indicate the movement of the cogwheels 
for the progression of inflammation. In healthy people, the inflammation is controlled by 
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the activation of anti‐inflammatory process after damage reparation. The cells (Treg and 
M2 macrophages) and molecules (IκBα, JunB, SOCS‐3, IFNR‐2, IL‐36RA, IL‐4, IL‐10, IL‐35, 
CD18, VHL, Tnip‐1, between others) involved in the anti‐inflammatory process are repre‐
sented in the gray cogwheels. The blue arrows indicate the movement of the cogwheels for 
the progression of anti‐inflammation. The “ghost” cogs (discontinuous lines) represent those 
dysfunctional molecules or cells that disrupt effectiveness in the control of inflammation, 
favoring the development of psoriasis.
Based on all the facts discussed in this chapter, we can conclude that psoriasis occurs in indi‐
viduals with the anti‐inflammatory regulation disrupted in immunological but also in non‐
immunological skin‐resident cells.
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Figure 1. Inflammatory process. The developing inflammation mechanism generated in the skin is represented in this 
cogwheel system, where innate immune response, adaptive immune response, angiogenesis and cellular proliferation 
are represented in independent but interconnected cogwheels. Brown cogwheels represent inflammatory mechanisms 
moving in a pro‐inflammatory sense (red arrows), where each cog represents one participant in inflammation (cell or 
molecule). Gray cogwheels represent the anti‐inflammatory mechanism spinning the wheels in the opposite direction 
(blue arrows) to regulate inflammation. The “ghost” cogs (discontinuous lines) represent dysfunctional cells or molecules 
that disrupt effectiveness in the control of inflammation, favoring the development of psoriasis. Some antibodies 
interfere with the spinning of pro‐inflammatory cogwheels, representing therapies with antibodies developed to control 
psoriasis. Question marks represent molecules to be discovered.
An Interdisciplinary Approach to Psoriasis
Author details
Sandra Rodríguez‐Martínez1, Juan C. Cancino‐Diaz2, Isaí Martínez‐Torrez1, Sonia M. Pérez‐Tapia1,3 
and Mario E. Cancino‐Diaz1*
*Address all correspondence to: mecancinod@gmail.com
1 Immunology Department, Escuela Nacional de Ciencias Biológicas‐IPN, Mexico City, 
Mexico
2 Microbiology Department, Escuela Nacional de Ciencias Biológicas‐IPN, Mexico City, 
Mexico
3 UDIBI, Escuela Nacional de Ciencias Biológicas‐IPN, Mexico City, Mexico
References
[1] Bechet PE. Psoriasis. A brief historical review.Archives of Dermatology and Syphilology. 
1936;33:327‐334
[2] Zanolli MD, Jayo MJ, Jayo JM, Blaine D, Hall J, Jorizzo JL. Evaluation of psoriatic plaques 
that spontaneously developed in a cynomolgus monkey (Macacafascicularis). Acta 
Dermato Venereologica – Supplementum (Stockh). 1989;146:58
[3] Regan SA, Marsell R, Ozmen I. First report of psoriatic‐like dermatitis and arthritis in 
a 4‐year‐old female spayed pug mix. Case Reports in Veterinary Medicine. 2015;2015:1‐4. 
DOI: 10.1155/2015/912509
[4] Gates AH, Karasek M. Hereditary absence of sebaceous glands in the mouse. Science. 
1965;148:1471‐1473. DOI: 10.1126/science.148.3676.1471
[5] Beamer WG, Pelsue SC, Shultz LD, Sundberg JP, Barker JE. The flaky skin (fsn) mutation 
in mice: map location and description of the anemia. Blood. 1995;86:3220‐3226
[6] Chen J, Roop DR. Genetically engineered mouse models for skin research: Taking the next 
step. Journal of Dermatology Sciences. 2008;52:1‐1. DOI: 10.1016/j.jdermsci.2008.03.012
[7] Bergers LI, Reijnders CM, van den Broek LJ, Spiekstra SW, de Gruijl TD, Weijers EM, 
Gibbs S. Immune‐competent human skin disease models. Drug Discovery Today. 
2016;21:1479‐1488. DOI: 10.1016/j.drudis.2016.05.008
[8] Boehncke WH, Sterry W, Hainzl A, Scheffold W, Kaufmann R. Psoriasiform architecture 
of murine epidermis overlying human psoriatic dermis transplanted onto SCID mice. 
Archives of Dermatological Research. 1994;286:325‐330
[9] Wrone‐Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. 
Journal of Clinical Investigation.1996;98:1878‐1887. DOI: 10.1172/JCI118989
Psoriatic Animal Models Developed for the Study of the Disease
http://dx.doi.org/10.5772/intechopen.68305
85
[10] van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus 
AM, Florencia E, Prens EP, Lubberts E. Imiquimod‐induced psoriasislike skin inflam‐
mation in mice is mediated via the IL‐23/IL‐17 axis. The Journal of Immunology. 
2009;182:5836‐5845. DOI: 10.4049/jimmunol.0802999; PMID: 19380832
[11] Duffy DL, Spelman LS, Martin NG. Psoriasis in Australian twins. Journal of the American 
Academy of Dermatology. 1993;29:428‐434
[12] Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, 
Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, 
Littman DR. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 
2009;139:485‐498.DOI: 10.1016/j.cell.2009.09.033
[13] Fahlén A, Engstrand L, Baker BS, Powles A, Fry L. Comparison of bacterial microbiota 
in skin biopsies from normal and psoriatic skin. Archives of Dermatological Research. 
2012;304:15‐22. DOI: 10.1007/s00403‐011‐1189‐x
[14] Zanvit P, Konkel JE, Jiao X, Kasagi S, Zhang D, Wu R, Chia C, Ajami NJ, Smith DP, 
Petrosino JF, Abbatiello B, Nakatsukasa H, Chen Q, Belkaid Y, Chen ZJ, Chen W. 
Antibiotics in neonatal life increase murine susceptibility to experimental psoriasis. 
Nature Communications. 2015;6:8424. DOI: 10.1038/ncomms9424
[15] Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring 
Harbor Perspectives in Biology. 2012;4:a006049. DOI: 10.1101/cshperspect.a006049
[16] Klement JF, Rice NR, Car BD, Abbondanzo SJ, Powers GD, Bhatt PH, Chen CH, Rosen 
CA, Stewart CL. IκBα deficiency results in a sustained NF‐κB response and severe wide‐
spread dermatitis in mice. Molecular and Cellular Biology. 1996;16:2341‐2349
[17] Li R, Wang J, Wang X, Zhou J, Wang M, Ma H, Xiao S. Increased βTrCP are associated 
with imiquimod‐induced psoriasis‐like skin inflammation in mice via NF‐κB signal‐
ing pathway. Gene. 2016;592:164‐171. DOI:10.1016/j.gene.2016.07.066. PubMed PMID: 
27476970
[18] Johansen C. IκBζ: A key protein in the pathogenesis of psoriasis. Cytokine. 2016;78:20‐21. 
DOI:10.1016/j.cyto.2015.11.015
[19] Trinh DV, Zhu N, Farhang G,Kim BJ, Huxford T. The nuclear IκB protein IκBζ specifi‐
cally binds NF‐κB p50 homodimers and forms a ternary complex on κB DNA. Journal of 
Molecular Biology.2008;379:122‐135. DOI: 10.1016/j.jmb.2008.03.060
[20] Johansen C, Mose M, Ommen P, Bertelsen T, Vinter H, Hailfinger S, Lorscheid S, 
Schulze‐Osthoff K, Iversen L. IκBζ is a key driver in the development of psoriasis. 
Proceedingsof the National Academy of Sciences U S A. 2015;112:E5825‐E5833. DOI: 
10.1073/pnas.1509971112
[21] Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, Scheuch H, Angel P, 
Tschachler E, Wagner EF. Psoriasis‐like skin disease and arthritis caused by inducible 
epidermal deletion of Jun proteins. Nature. 2005;437:369‐375. DOI: 10.1038/nature03963
An Interdisciplinary Approach to Psoriasis86
[22] Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, Itami S, Nickoloff BJ, 
DiGiovanni J. Stat3 links activated keratinocytes and immunocytes required for devel‐
opment of psoriasis in a novel transgenic mouse model. Nature Medicine. 2005;11:43‐49. 
DOI: 10.1038/nm1162
[23] Uto‐Konomi A, Miyauchi K, Ozaki N, Motomura Y, Suzuki Y, Yoshimura A, Suzuki S, 
Cua D, Kubo M. Dysregulation of suppressor of cytokine signaling 3 in keratinocytes 
causes skin inflammation mediated by interleukin‐20 receptor‐related cytokines. PLoS 
One. 2012;7:e40343. DOI: 10.1371/journal.pone.0040343
[24] Hida S, Ogasawara K, Sato K, Abe M, Takayanagi H, Yokochi T, Sato T, Hirose S, Shirai T, 
Taki S, Taniguchi T. CD8(+) T cell‐mediated skin disease in mice lacking IRF‐2, the tran‐
scriptional attenuator of interferon‐alpha/beta signaling. Immunity. 2000;13:643‐655. 
DOI:10.1016/S1074‐7613(00)00064‐9
[25] Nestle FO, Conrad C, Tun‐Kyi A, Homey B, Gombert M, Boyman O, Burg G, Liu YJ, 
Gilliet M. Plasmacytoidpredendritic cells initiate psoriasis through interferon‐alpha pro‐
duction. The Journal of Experimental Medicine. 2005;202:135‐143
[26] Blumberg H, Dinh H, Trueblood ES, Pretorius J, Kugler D, Weng N, Kanaly ST, Towne 
JE, Willis CR, Kuechle MK, Sims JE, Peschon JJ. Opposing activities of two novel mem‐
bers of the IL‐1 ligand family regulate skin inflammation. The Journal of Experimental 
Medicine. 2007;204:2603‐2614. DOI: 10.1084/jem.20070157
[27] Towne E, Sims JE. IL‐36 in psoriasis. Current Opinion in Pharmacology. 2012;4:486‐490. 
DOI: 10.1016/j.coph.2012.02.009
[28] Lindroos J, Svensson L, Norsgaard H, Lovato P, Moller K, Hagedorn PH, Olsen GM, 
Labuda T. IL‐23‐mediated epidermal hyperplasia is dependent on IL‐6. Journal of 
Investigative Dermatology. 2011;131:1110‐1118. DOI: 10.1038/jid.2010.432
[29] Zhang J, Lin Y, Li C, Zhang X, Cheng L, Dai L, Wang Y, Wang F, Shi G, Li Y, Yang Q, Cui 
X, Liu Y, Wang H, Zhang S, Yang Y, Xiang R, Li J, Yu D, Wei Y, Deng H. IL‐35 deceler‐
ates the inflammatory process by regulating inflammatory cytokine secretion and M1/
M2 macrophage ratio in psoriasis. The Journal of Immunology. 2016;197:2131‐2144. DOI: 
10.4049/jimmunol.1600446
[30] Torales‐Cardeña A, Martínez‐Torres I, Rodríguez‐Martínez S, Gómez‐Chavez F, Cancino‐
Diaz JC, Vázquez‐Sánchez EA, Cancino‐Diaz‐ ME. Cross Talk between Proliferative, 
Angiogenic, and Cellular mechanisms orchestred by HIF‐1α in psoriasis. Mediators of 
Inflammation. 2015;2015:1‐11. DOI:10.1155/2015/607363
[31] Bullard DC, Scharffetter‐Kochanek K, McArthur MJ, Chosay JG, McBride ME, Montg omery 
CA, Beaudet AL. A polygenic mouse model of psoriasiform skin diseas in CD18‐deficient 
mice. Proceedings of the National Academy of Sciences U S A. 1996;93:2116‐2121. DOI: 
10.1073/pnas.93.5.2116
[32] Singh K, Gatzka M, Peters T, Borkner L, Hainzl A, Wang H, Sindrilaru A, Scharffetter‐
Kochanek K. Reduced CD18 levels drive regulatory T cell conversion into Th17 
Psoriatic Animal Models Developed for the Study of the Disease
http://dx.doi.org/10.5772/intechopen.68305
87
cells in the CD18hypo PL/J mouse model of psoriasis. The Journal of Immunology. 
2013;190:2544‐2553. DOI: 10.4049/jimmunol.1202399
[33] Wang H, Peters T, Kess D, Sindrilaru A, Oreshkova T, Van Rooijen N, Stratis A, Renkl AC, 
Sunderkötter C, Wlaschek M, Haase I, Scharffetter‐Kochanek K. Activated macrophages 
are essential in a murine model for T cell‐mediated chronic psoriasiform skin inflamma‐
tion. Journal of Clinical Investigation. 2006;116:2105‐2114. DOI: 10.1172/JCI27180
[34] Schukur L, Geering B, Charpin‐El Hamri G, Fussenegger M. Implantable synthetic‐
cytokine converter cells with AND‐gate logic treat experimental psoriasis. Science 
Translational Medicine. 2015;7318:318ra201. DOI: 10.1126/scitranslmed.aac4964
[35] Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS. Transgenic delivery of 
VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. 
Blood. 2003;102:161‐168. PMID: 12649136
[36] Wolfram JA, Diaconu D, Hatala DA, Rastegar J, Knutsen DA, Lowther A, Askew D, 
Gilliam AC, McCormick TS, Ward NL. Keratinocyte but not endothelial cell‐specific 
overexpression of Tie2 leads to the development of psoriasis. American Journal of 
Pathology. 2009;174:1443‐1458. DOI: 10.2353/ajpath.2009.080858
[37] Li AG, Wang D, Feng XH, Wang XJ. Latent TGFbeta1 overexpression in keratinocytes 
results in a severe psoriasis‐like skin disorder. EMBO Journal. 2004;23:1770‐1781. 
PubMed PMID: 15057277; PubMed Central PMCID: PMC394237
[38] Wang X, Sun J, Hu J. IMQ induced K14‐VEGF mouse: A stable and long‐term mouse 
model of psoriasis‐like inflammation. PLoS One. 2015;10:e0145498. DOI: 10.1371/journal.
pone.0145498. eCollection 2015
[39] Cook PW, Piepkorn M, Clegg CH, Plowman GD, DeMay JM, Brown JR, Pittelkow MR. 
Transgenic expression of the human amphiregulin gene induces a psoriasis‐like pheno‐
type. Journal of Clinical Investigation. 1997;100:2286‐2294. PMID: 9410906
[40] Cook PW, Brown JR, Cornell KA, Pittelkow MR. Suprabasal expression of human amphi‐
regulin in the epidermis of transgenic mice induces a severe, early‐onset, psoriasis‐like 
skin pathology: Expression of amphiregulin in the basal epidermis is also associated 
with synovitis. Experimental Dermatology. 2004;13:347‐356. PubMedPMID: 15186320
[41] Romanowska M, Reilly L, Palmer CN, Gustafsson MC, Foerster J. Activation of PPAR 
beta/delta causes a psoriasis‐like skin disease in vivo. PLoS One. 2010;5:e9701. DOI: 
10.1371/journal.pone.0009701. PubMed PMID: 20300524
[42] Romanowska M, al Yacoub N, Seidel H, Donandt S, Gerken H, Phillip S, Haritonova 
N, Artuc M, Schweiger S, Sterry W, Foerster J. PPARdelta enhances keratinocyte pro‐
liferation in psoriasis and induces heparin‐binding EGF‐like growth factor. Journal of 
Investigative Dermatology. 2008;128:110‐124. PubMed PMID: 17637826.
[43] Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, Heim M, Flühmann B, Desvergne B, 
Wahli W. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. 
Genes & Development.2001;15:3263‐3277. PubMed PMID: 11751632
An Interdisciplinary Approach to Psoriasis88
[44] Pasparakis M, Courtois G, Hafner M, Schmidt‐Supprian M, Nenci A, Toksoy A, 
Krampert M, Goebeler M, Gillitzer R, Israel A, Krieg T, Rajewsky K, Haase I. TNF‐medi‐
ated inflammatory skin disease in mice with epidermis‐specific deletion of IKK2. Nature. 
2002;417:861‐866. PubMed PMID: 12075355
[45] Grinberg‐Bleyer Y, Dainichi T, Oh H, Heise N, Klein U, Schmid RM, Hayden MS, Ghosh 
S. Cutting edge: NF‐κB p65 and c‐Rel control epidermal development and immune 
homeostasis in the skin. The Journal of Immunology. 2015;194:2472‐2476. DOI: 10.4049/
jimmunol.1402608
[46] Zhang JY, Green CL, Tao S, Khavari PA. NF‐κB RelA opposes epidermal proliferation 
driven by TNFR1 and JNK. Genes & Development. 2004;18:17‐22
[47] Monnier J, Samson M. Prokineticins in angiogenesis and cancer. Cancer Letters. 
2010;296:144‐149. DOI: 10.1016/j.canlet.2010.06.011
[48] Shojaei F, Singh M, Thompson JD, Ferrara N. Role of Bv8 in neutrophil‐dependent 
angiogenesis in a transgenic model of cancer progression. Proceedings of the National 
Academy of Sciences U S A. 2008;105:2640‐2645. DOI:10.1073/pnas.0712185105
[49] Martucci C, Franchi S, Giannini E, Tian H, Melchiorri P, Negri L, Sacerdote P. Bv8, the 
amphibian homologue of the mammalian prokineticins, induces a proin‐flammatory 
phenotype of mouse macrophages. British Journal of Pharmacology. 2006;147:225‐234. 
DOI: 10.1038/sj.bjp.0706467
[50] He X, Shen C, Lu Q, Li J, Wei Y, He L, Bai R, Zheng J, Luan N, Zhang Z, Rong M, Lai 
R. Prokineticin 2 Plays a Pivotal Role in Psoriasis. EBioMedicine. 2016;13:248‐261. DOI: 
10.1016/j.ebiom.2016.10.022
[51] Callahan JA, Hammer GE, Agelides A, Duong BH, Oshima S, North J, Advincula R, 
Shifrin N, Truong HA, Paw J, Barrera J, DeFranco A, Rosenblum MD, Malynn BA, Ma A. 
Cutting edge: ABIN‐1 protects against psoriasis by restricting MyD88 signals in dendritic 
cells. The Journal of Immunology. 2013;191:535‐539. DOI:10.4049/jimmunol.1203335
[52] Ippagunta SK, Gangwar R, Finkelstein D, Vogel P, Pelletier S, Gingras S, Redecke V, 
Häcker H. Keratinocytes contribute intrinsically to psoriasis upon loss of Tnip1 function. 
Proceedings of the National Academy of Sciences U S A. 2016;113:E6162‐E6171. PubMed 
PMID: 27671649
[53] Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development 
success rates for investigational drugs. Nature Biotechnology. 2014;32:40‐51. DOI: 
10.1038/nbt.2786
[54] Krueger GG, Jorgensen CM. Experimental models for psoriasis. Journal of Investigative 
Dermatology. 1990;95:56S‐58S. DOI: 10.1111/1523‐1747.ep12505791
[55] Van Ruissen F, de Jongh GJ, Zeeuwen PL, Van Erp PE, Madsen P, Schalkwijk J. 
Induction of normal and psoriatic phenotypes in submerged keratinocyte cultures. 
Journal of Cellular Physiology. 1996;168:442‐452. DOI: 10.1002/(SICI)1097‐4652(199608) 
168:2<442::AID‐JCP23>3.0.CO;2‐3
Psoriatic Animal Models Developed for the Study of the Disease
http://dx.doi.org/10.5772/intechopen.68305
89
[56] Auriemma M, Brzoska T, Klenner L, Kupas V, Goerge T, Voskort M, Zhao Z, Sparwasser 
T, Luger TA, Loser K. α‐MSH‐stimulated tolerogenic dendritic cells induce functional 
regulatory T cells and ameliorate ongoing skin inflammation. Journal of Investigative 
Dermatology. 2012;132:1814‐1824. DOI: 10.1038/jid.2012.59
[57] Van den Bogaard EH, Tjabringa GS, Joosten I, Vonk‐Bergers M, van Rijssen E, Tijssen 
HJ, Erkens M, Schalkwijk J, Koenen HJ. Crosstalk between keratinocytes and T cells 
in a 3D microenvironment: A model to study inflammatory skin diseases. Journal of 
Investigative Dermatology. 2014;134:719‐727. DOI: 10.1038/jid.2013.417
[58] Wufuer M, Lee G, Hur W, JeonB, KimB, ChoiT,LeeS. Skin‐on‐a‐chip model simulat‐
ing inflammation, edema and drug‐based treatment. Scientific Reports. 2016;6:37471. 
DOI:10.1038/srep37471
An Interdisciplinary Approach to Psoriasis90
